Microdispenser Tech Powers Lab Automation Breakthroughs

Picoliter microdispensers can place as little as 10 pL and up to 100 µL per actuation, and that range drives a shift toward high-throughput miniaturized assays with less reagent waste.

With that in mind, these systems, from SCIENION’s sciDROP PICO and sciFLEXARRAYER to PolyPico Tech platforms, offer non-contact, drop-on-demand dispensing for a wide range of viscosities and sample types. In practice, labs can move from trial-and-error liquid handling to reproducible, automated workflows that scale, especially in diagnostics and drug discovery.

We’ve known for years that precision liquid handling matters (but the scale now matters more). Microdispensing technology underpins the production of more than 3 billion diagnostic tests each year, a figure that reflects global demand and the robustness of automated dispensing in manufacturing, clinical labs, and point-of-care settings. Automated microdispensing improves reproducibility and consistency, a must-have for clinical diagnostics and large-scale screening programs where error rates can derail timelines and budgets.

On the lab side, microdispensing accelerates the development of biosensors, microarrays, and lab-on-chip devices by enabling ultra-miniaturized reagent placement. S typical advanced microarray (high-throughput, chip-based assay platform with thousands of spots) system can place thousands of spots per run, often in the thousands-to-tens-of-thousands range, with throughput gains of 10-100x for multiplex assays. In practical terms, faster assay cycles, smaller reagent footprints, and the ability to test more targets per plate follow.

Key hardware configurations now allow up to 8 dispensing capillaries per microarray dispenser (as seen in sciFLEXARRAYER S3), enabling higher throughput and multiplexing on the same substrate.

Industry data show reagent volumes reduced by more than 100x with picoliter dispensing compared with traditional methods, and the time to dispense hundreds or thousands of spots can be seconds to minutes. Some acoustic systems claim 0% dead volume, which translates into less waste and more efficient use of expensive reagents.

From a business lens, labs adopting microdispensing report 3-10x improvements in assay reproducibility and reductions in error rates when moving from manual to automated liquid handling. The potential financial impact is notable: industry estimates suggest high-throughput screening labs could save $2-5 million annually on reduced reagent usage alone. The global footprint is broad, more than 50 countries host microdispenser installations across BioDot, PolyPico, and SCIENION, with ongoing product launches in 2025 signaling continued momentum.

In diagnostics and research, microdispensing is shifting what’s feasible. For SARS-CoV-2 and other infectious disease work, 25 mm² areas support multiplexed microarrays, with demonstrations showing up to 28 peptide epitopes and 7 proteins per microarray.

This multiplexing, enabled by drop-on-demand systems, directly improves assay coverage while reducing processing time. In live-cell work, recent hardware advances emphasize flexibility to handle a broad viscosity range while minimizing shear stress, a win for sensitive cell types.

Industry events reflect the pace. MicroTAS 2025 in Adelaide, November 2-6, 2025, will spotlight miniaturized fluid handling systems as a driver of faster, more reliable life sciences automation. Major players, SCIENION, PolyPico, BioDot, continue to push systems that support COVID-19 workflows, genomics, proteomics, and cytogenetics. Real-world testimonials from UNC Health and the University of Oviedo, plus Cytiva, underscore practical benefits in hospital and academic settings.

By the way, multidisciplinary teams matter here. Microdispensing isn’t a single-tool fix; it’s a platform that integrates with LIMS, robotic arms, and data analytics to manage throughput, traceability, and quality control across large portfolios of assays. The result is faster, more consistent data, fewer sources of variability, and better scalability for projects that span thousands of targets.

Okay, let’s move on to what this means for you. If you’re building or upgrading labs for diagnostics, drug screening, or biosensor development, you should expect three things: first, a clear path to reducing reagent waste and cut-down times; second, the ability to run highly multiplexed assays on the same chip or plate; third, proven improvements in reproducibility that translate to steadier downstream results and more reliable decision-making.

Author’s perspective: I’ve seen teams justify microdispensing by the numbers, >100x reagent reduction, seconds-to-minutes dispensing of hundreds of spots, multi-capillary platforms enabling multiplexing, and a tangible uplift in assay robustness. In the end, these tools are for the long term that will help to continue researching and improving. They’re not magic; they’re a practical upgrade to modern lab workflows.

Practical takeaways:

• Target systems that support 10 pL to 100 µL per dispense and allow 8-capillary multiplexing for higher throughput.
• Look for zero-dead-volume options and live-cell compatibility to protect sensitive samples.
• Expect measurable cost savings in HTS environments and faster timelines in diagnostic development.
• Plan for integration with existing automation stacks and data pipelines to unlock full throughput potential.

What do you think? Do you think your lab could benefit from adding a microdispensing layer to your automated workflows? Share your experiences in the comments. If you want to go deeper, I can walk you through a step-by-step evaluation of which platform fits your throughput, viscosity range, and cell compatibility. I’ve watched labs improve when they adopt these tools, they are tools for the long term that will help to continue researching and improving.

Kenji Tanaka